RXRX — Recursion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.23bn
- $1.70bn
- $74.68m
Recursion Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data
U.S. STOCKS ON THE MOVE-Wells Fargo, American Express, Mondelez
U.S. STOCKS ON THE MOVE-TreeHouse Foods, Sarepta Therapeutics, Walmart
U.S. STOCKS ON THE MOVE-Morgan Stanley, Fluence Energy, Bank of New York
AI-based drug developers rise on US FDA's plans to replace animal testing
U.S. STOCKS ON THE MOVE-BridgeBio Pharma, NetApp, Talen Energy
U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines
Nvidia-backed Recursion Pharmaceuticals falls on bigger-than-expected Q4 loss
Recursion Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Recursion Pharmaceuticals Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Recursion Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Recursion Presents Phase 2 Data For REC-994 in CCM
Brief: Recursion Pharmaceuticals Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Brief: Recursion Pharmaceuticals Inc - Files Prospectus Supplement
Brief: Recursion Reports Interim Phase 1 Clinical Data For Rec-617 Monotherapy
Brief: Recursion And Exscientia Shareholders Approve The Proposed Combination
Recursion Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Recursion Pharmaceuticals Q3 Net Income USD -95.8 Million